Kazia Therapeutics (KZIA) director reports ADS option awards and vesting

Rhea-AI Filing Summary

Kazia Therapeutics Ltd director Robert F. Apple filed his initial ownership report, showing two American Depositary Share (ADS) option awards. One ADS option covers 2,000 underlying ADSs at an exercise price of $0.3348 per ADS, expiring on April 30, 2027, and vests in equal quarterly installments over three years beginning on April 30, 2024. A second ADS option covers 75,000 underlying ADSs at an exercise price of $6.58 per ADS, expiring on July 3, 2027, and vests in three equal annual installments beginning on July 3, 2025. Each option converts into ADSs upon exercise, and each ADS may be represented by 500 ordinary shares of Kazia Therapeutics.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider APPLE ROBERT F

Role Director

Type	Security	Shares	Price	Value
holding	American Depositary Share Option (Right to Buy)	--	--	--
holding	American Depositary Share Option (Right to Buy)	--	--	--

Holdings After Transaction: American Depositary Share Option (Right to Buy) — 77,000 shares (Direct)

Footnotes (3)

1. F1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 30, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on April 30, 2024.
2. F2. Each ADS option is convertible into ADSs upon exercise. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.
3. F3. The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 03/18/2026 - 05:47 PM Learn about SEC filing dates

FAQ

What insider holdings did Kazia Therapeutics (KZIA) director Robert F. Apple report?

Robert F. Apple reported two ADS option awards over Kazia Therapeutics securities. One covers 2,000 ADSs at $0.3348, and another covers 75,000 ADSs at $6.58, both expiring in 2027 with multi-year vesting schedules.

How do Robert F. Apple’s Kazia Therapeutics (KZIA) ADS options vest?

One Kazia ADS option vests in equal quarterly installments over three years starting April 30, 2024. The second vests in three equal annual installments beginning July 3, 2025, in each case requiring his continuous service through the applicable vesting dates.

What are the exercise prices and expirations of Robert F. Apple’s KZIA ADS options?

Apple holds an ADS option at an exercise price of $0.3348 per ADS expiring April 30, 2027, and another at $6.58 per ADS expiring July 3, 2027. Both relate to American Depositary Shares of Kazia Therapeutics.

How are Kazia Therapeutics (KZIA) ADSs related to ordinary shares in this filing?

Each ADS option converts into ADSs upon exercise. Each ADS may be represented by 500 ordinary shares of Kazia Therapeutics, which can be received if the holder surrenders the ADSs and withdraws the corresponding number of ordinary shares.

Does this Kazia Therapeutics (KZIA) Form 3 show insider buying or selling?

This Form 3 records Robert F. Apple’s existing ADS option awards and vesting terms. It does not report open-market purchases or sales of Kazia Therapeutics securities, only his option-based derivative positions and their key conditions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

APPLE ROBERT F

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS

LEVEL 24, 300 BARANGAROO AVE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Share Option (Right to Buy)	(1)	04/30/2027	American Depositary Shares(2)	2,000	$0.3348	D
American Depositary Share Option (Right to Buy)	(3)	07/03/2027	American Depositary Shares(2)	75,000	$6.58	D

Explanation of Responses:

1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in equal quarterly installments over three years beginning on April 30, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on April 30, 2024.

2. Each ADS option is convertible into ADSs upon exercise. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.

3. The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jeffrey Bonacorda, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)